{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:56:17Z","timestamp":1791608177288,"version":"4.3.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Healthcare Pvt Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Macular edema secondary to retinal vein occlusion (RVO) is an important cause of loss of vision. Intravitreal injections (IVI) of anti-vascular endothelial growth factor (VEGF) are the standard of care in this disease, as shown in numerous randomized controlled trials. The purpose of this study was to study the efficacy and safety of ranibizumab, an anti-VEGF agent, in the real-world setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was 48\u2009weeks, open-label, prospective, multicentre, observational study. Patients diagnosed with ME secondary to RVO were treated with IVI of Ranibizumab 0.5\u2009mg in real-world conditions. Efficacy was measured by improvement seen in best-corrected visual acuity (BCVA) in terms of Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores and change in central retinal thickness (CRT) measured by optical coherence tomography.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One hundred eyes of 100 patients (79 with branch retinal vein occlusion and 21 with central retinal vein occlusion) were recruited in the study. The mean (standard deviation, SD) BCVA was 52.8 (21.99) letters at baseline and 62.3 (24.40) letters at week 48. From baseline, there was a significant improvement in BCVA by 7.7 letters (<jats:italic>p<\/jats:italic>\u2009=\u20090.001) at 48\u2009weeks. The mean (SD) of CRT was 479.9 (216.25) \u03bcm at baseline and it decreased significantly to 284.9 (171.35) \u03bcm at week 48 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). During the study period, the average number of intravitreal injections was 3.5 per patient. There was no report of endophthalmitis in any eye.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Ranibizumab is well tolerated and effective in treating macular edema secondary to RVO in real-world clinical settings. However, there is under-treatment compared to controlled clinical trials, and the gain in vision is sub-optimal with under-treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Clinical Trials Registry - India: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=5302&amp;EncHid=&amp;modid=&amp;compid=%27,%275302det%27\">CTRI\/2015\/07\/005985<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-020-01757-7","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T20:47:24Z","timestamp":1610484444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9688-5859","authenticated-orcid":false,"given":"Raja","family":"Narayanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Kelkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahir","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Soman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Sudhalkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaydeep","family":"Walinjkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utkarsh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Maksane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"issue":"1","key":"1757_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12886-018-0701-x","volume":"18","author":"K Brogan","year":"2018","unstructured":"Brogan K, Precup M, Rodger A, Young D, Gilmour DF. Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab. BMC Ophthalmol. 2018;18(1):37.","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"1757_CR2","first-page":"1563","volume":"17","author":"D Wang","year":"2019","unstructured":"Wang D, Kunfang W, Juanjuan W, Wang J, Xu G, Chen Z. Clinical efficacy evaluation of treatment of different degrees of retinal vein occlusion with ranibizumab combined with an argon ion laser. Exp Ther Med. 2019;17(3):1563\u20138.","journal-title":"Exp Ther Med."},{"key":"1757_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.exer.2013.03.005","volume":"111","author":"MH Kang","year":"2013","unstructured":"Kang MH, Balaratnasingam C, Yu PK, Morgan WH, McAllister IL, Cringle SJ, et al. Alterations to vascular endothelium in the optic nerve head in patients with vascular comorbidities. Exp Eye Res. 2013;111:50\u201360.","journal-title":"Exp Eye Res"},{"issue":"1","key":"1757_CR4","first-page":"890","volume":"15","author":"H Liu","year":"2018","unstructured":"Liu H, Li S, Zhang Z, Shen J. Predicting the visual acuity for retinal vein occlusion after ranibizumab therapy with an original ranking for macular microstructure. Exp Ther Med. 2018;15(1):890\u20136.","journal-title":"Exp Ther Med"},{"issue":"1","key":"1757_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/IAE.0b013e318260246f","volume":"33","author":"JB Jonas","year":"2013","unstructured":"Jonas JB, Nangia V, Khare A, Sinha A, Lambat S. Prevalence and associations of retinal vein occlusions: the Central India eye and medical study. Retina. 2013;33(1):152\u20139.","journal-title":"Retina."},{"key":"1757_CR6","unstructured":"Food and Drug Administration. Accessdata.fda.gov. (2019). [online] Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125156s114lbl.pdf [Accessed 04 March 2019]."},{"issue":"6","key":"1757_CR7","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","volume":"117","author":"PA Campochiaro","year":"2010","unstructured":"Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102\u201312.e1. https:\/\/doi.org\/10.1016\/j.ophtha.2010.02.021.","journal-title":"Ophthalmology"},{"issue":"10","key":"1757_CR8","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.0308","volume":"118","author":"PA Campochiaro","year":"2011","unstructured":"Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118(10):2041\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2011.02.0308.","journal-title":"Ophthalmology"},{"key":"1757_CR9","doi-asserted-by":"publisher","unstructured":"Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014;121(7):1414\u201320.e1. doi: https:\/\/doi.org\/10.1016\/j.ophtha.2014.01.027.","DOI":"10.1016\/j.ophtha.2014.01.027"},{"key":"1757_CR10","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1097\/IAE.0000000000000111","volume":"34","author":"T Brynskov","year":"2014","unstructured":"Brynskov T, Kemp H, Sorensen TL. Intravitreal ranibizumab for retinal vein occlusion through I year in clinical practice. Retina. 2014;34:1637\u201343.","journal-title":"Retina"},{"key":"1757_CR11","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2147\/OPTH.S107594","volume":"10","author":"Y Sakanishi","year":"2016","unstructured":"Sakanishi Y, Lee A, Usui-Ouchi A, Ito R, Ebihara N. Twelve-month outcomes in patients with retinal vein occlusion treated with low-frequency intravitreal ranibizumab. Clin Ophthalmol. 2016;10:1161\u20135.","journal-title":"Clin Ophthalmol"},{"key":"1757_CR12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/eye.2014.308","volume":"29","author":"AJ Lotery","year":"2015","unstructured":"Lotery AJ, Regnier S. Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA. Eye (Lond). 2015;29:380\u20137.","journal-title":"Eye (Lond)"},{"key":"1757_CR13","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.2147\/OPTH.S209253","volume":"13","author":"J Callizo","year":"2019","unstructured":"Callizo J, Ziemssen F, Bertelmann T, Feltgen N, V\u00f6geler J, Koch M, Eter N, Liakopoulos S, Schmitz-Valckenberg S, Spital G. Real-world data: ranibizumab treatment for retinal vein occlusion in the OCEAN study. Clin Ophthalmol. 2019;13:2167\u201379.","journal-title":"Clin Ophthalmol"},{"key":"1757_CR14","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1007\/s00417-017-3719-5","volume":"255","author":"I Chatziralli","year":"2017","unstructured":"Chatziralli I, Theodossiadis G, Kabanarou SA, Parikakis E, Xirou T, Mitropoulos P, Theodossiadis P. Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study. Graefes Arch Clin Exp Ophthalmol. 2017;255:1899\u2013905.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1757_CR15","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2147\/OPTH.S60893","volume":"8","author":"S Kiss","year":"2014","unstructured":"Kiss S, Liu Y, Brown J, Holekamp NM, Almony A, Campbell J, Kowalski JW. Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol. 2014;8:1611.","journal-title":"Clin Ophthalmol"},{"key":"1757_CR16","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.2147\/OPTH.S89147","volume":"9","author":"PL Lip","year":"2015","unstructured":"Lip PL, Malick H, Damer K, Elsherbiny S, Darrad KM, Mushtaq B, Mitra A, Stavrou P, Yang Y. One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK. Clin Ophthalmol. 2015;9:1779.","journal-title":"Clin Ophthalmol"},{"key":"1757_CR17","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/mt.2008.10","volume":"16","author":"PA Campochiaro","year":"2008","unstructured":"Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther. 2008;16:791\u20139.","journal-title":"Mol Ther"},{"issue":"5","key":"1757_CR18","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.ophtha.2016.01.011","volume":"123","author":"M Larsen","year":"2016","unstructured":"Larsen M, Waldstein SM, Boscia F, Gerding H, Mon\u00e9s J, Tadayoni R, et al. (CRYSTAL study group). Individualized Ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL study. Ophthalmology. 2016;123(5):1101\u201311.","journal-title":"Ophthalmology"},{"issue":"1","key":"1757_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5005\/jp-journals-10008-1213","volume":"11","author":"GM Reis","year":"2017","unstructured":"Reis GM, Grigg J, Chua B, Lee A, Lim R, Higgins R, et al. Incidence of intraocular pressure elevation following Intravitreal Ranibizumab (Lucentis) for age-related macular degeneration. J Curr Glaucoma Pract. 2017;11(1):3\u20137.","journal-title":"J Curr Glaucoma Pract"},{"key":"1757_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ajoc.2018.06.005","volume":"11","author":"AM Wu","year":"2018","unstructured":"Wu AM, Wu CM, Greenberg PB, Yu F, Lum F, Coleman AL. The use of bevacizumab and ranibizumab for branch retinal vein occlusion in medicare beneficiaries. Am J Ophthalmol Case Rep. 2018;11:105\u20138.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"1","key":"1757_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ajo.2013.08.013","volume":"157","author":"MH Tan","year":"2014","unstructured":"Tan MH, McAllister IL, Gillies ME, Verma N, Banerjee G, Smithies LA, et al. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion. Am J Ophthalmol. 2014;157(1):237\u201347.","journal-title":"Am J Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01757-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-020-01757-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01757-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T20:55:10Z","timestamp":1610484910000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-020-01757-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1757"],"URL":"https:\/\/doi.org\/10.1186\/s12886-020-01757-7","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,12]]},"assertion":[{"value":"16 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The purpose of the study was informed to all patients, and their written consent was obtained in accordance with the declaration of Helsinki. The study was approved by the following Ethics Committees at respective sites.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Utkarsh Shah is a medical advisor and Dr. Nitin Maksane is a franchise medical head. Both are employees of Novartis Healthcare Private Limited, India. Dr. Raja Narayanan, Dr. Aditya Kelkar, Dr. Zahir Abbas, Dr. Neha Goel, Dr. Manoj Soman, Dr. Naveen Naik, Dr. Aditya Sudhalkar and Dr. Jaydeep Walinjkar were the investigators of the regulatory mandated phase 4 study undertaken by Novartis Healthcare Private Limited. Although the study was funded by Novartis Healthcare Private Limited, there was no interference with the independent analysis of the data. They do not have any competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}